Gossamer Bio, Inc.
GOSS • NASDAQ
Gossamer Bio, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Faheem Hasnain, with a market cap of $81.3M.
CEOFaheem Hasnain
Next Earnings
Upcoming earnings announcement for Gossamer Bio, Inc.
Date
Thursday, May 14, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.17
Revenue Estimate
$5.0M
Earnings History
Past 12 earnings reports for Gossamer Bio, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 17, 2026 | Q4 2025 | -$0.21Est: -$0.20 | -5.0% | $13.8MEst: $7.6M | +82.7% | — |
| Nov 5, 2025 | Q3 2025 | -$0.21Est: -$0.19 | -10.5% | $13.3MEst: $6.3M | +112.4% |  10-Q |
| Aug 5, 2025 | Q2 2025 | -$0.17Est: -$0.18 | +5.6% | $11.5MEst: $5.0M | +127.9% | 10-Q |
| May 15, 2025 | Q1 2025 | -$0.16Est: -$0.19 | +15.8% | $9.9MEst: $4.0M | +150.4% | 10-Q |
| Mar 13, 2025 | Q4 2024 | -$0.15Est: -$0.17 | +11.8% | $9.4MEst: $7.0M | +33.6% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.14Est: -$0.15 | +6.7% | $9.5MEst: $7.7M | +23.1% | 10-Q |
| Aug 12, 2024 | Q2 2024 | $0.22Est: $0.23 | -4.3% | $95.8MEst: $114.3M | -16.1% | 10-Q |
| May 7, 2024 | Q1 2024 | -$0.19Est: -$0.18 | -5.6% | - | — | 10-Q |
| Mar 5, 2024 | Q4 2023 | -$0.21Est: -$0.21 | 0.0% | - | — | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.21Est: -$0.26 | +19.2% | - | — | — |
| Aug 8, 2023 | Q2 2023 | -$0.45Est: -$0.49 | +8.2% | - | — | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.52Est: -$0.53 | +1.9% | - | — | 10-Q |